Effectiveness of platelet function analysis-guided aspirin and/or clopidogrel therapy in preventing secondary stroke : A systematic review and meta-analysis
Yan, Ann-Rong (University of Canberra)
Naunton, Mark (University of Canberra)
Peterson, Gregory M. (University of Tasmania)
Fernandez-Cadenas, Israel (Institut d'Investigació Biomèdica Sant Pau)
Mortazavi, Reza (University of Canberra)
Universitat Autònoma de Barcelona

Fecha:	2020
Resumen:	Antiplatelet medications such as aspirin and clopidogrel are used following thrombotic stroke or transient ischemic attack (TIA) to prevent a recurrent stroke. However, the antiplatelet treatments fail frequently, and patients experience recurrent stroke. One approach to lower the rates of recurrence may be the individualized antiplatelet therapies (antiplatelet therapy modification (ATM)) based on the results of platelet function analysis (PFA). This review was undertaken to gather and analyze the evidence about the effectiveness of such approaches. We searched Medline, CINAHL, Embase, Web of Science, and Cochrane databases up to 7 January 2020. Two observational studies involving 1136 patients were included. The overall effects of PFA-based ATM on recurrent strokes (odds ratio (OR) 1. 05; 95% confidence interval (CI) 0. 69 to 1. 58), any bleeding risk (OR 1. 39; 95% CI 0. 92 to 2. 10) or death hazard from any cause (OR 1. 19; 95% CI 0. 62 to 2. 29) were not significantly different from the standard antiplatelet therapy without ATM. The two studies showed opposite effects of PFA-guided ATM on the recurrent strokes in aspirin non-responders, leading to an insignificant difference in the subgroup meta-analysis (OR 1. 59; 95% CI 0. 07 to 33. 77), while the rates of any bleeding events (OR 1. 04; 95% CI 0. 49 to 2. 17) or death from any cause (OR 1. 17; 95% CI 0. 41 to 3. 35) were not significantly different between aspirin non-responders with ATM and those without ATM. There is a need for large, randomized controlled trials which account for potential confounders such as ischemic stroke subtypes, technical variations in the testing protocols, patient adherence to therapy and pharmacogenetic differences.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Antiplatelet ; Antiplatelet therapy modification ; Aspirin ; Clopidogrel ; High on-treatment platelet reactivity ; Ischemic stroke ; Platelet function analysis ; Secondary stroke prevention ; TIA
Publicado en:	Journal of clinical medicine, Vol. 9 Núm. 12 (december 2020) , p. 1-15, ISSN 2077-0383

DOI: 10.3390/jcm9123907
PMID: 33271959

15 p, 2.4 MB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut de Recerca Sant Pau
Artículos > Artículos de investigación
Artículos > Artículos publicados